DrugPatentWatch Database Preview

Avanir Pharms Company Profile

« Back to Dashboard

What is the competitive landscape for AVANIR PHARMS, and when can generic versions of AVANIR PHARMS drugs launch?

AVANIR PHARMS has two approved drugs.

There are eighteen US patents protecting AVANIR PHARMS drugs.

There are two hundred and ninety-six patent family members on AVANIR PHARMS drugs in thirty-one countries and eleven supplementary protection certificates in ten countries.

Summary for Avanir Pharms

International Patents:	296
US Patents:	18
Tradenames:	2
Ingredients:	2
NDAs:	2

Drugs and US Patents for Avanir Pharms

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Avanir Pharms	ONZETRA XSAIL	sumatriptan succinate	POWDER;INHALATION	206099-001	Jan 27, 2016		RX	Yes	Yes	10,076,615
Avanir Pharms	ONZETRA XSAIL	sumatriptan succinate	POWDER;INHALATION	206099-001	Jan 27, 2016		RX	Yes	Yes	8,550,073		Y
Avanir Pharms	NUEDEXTA	dextromethorphan hydrobromide; quinidine sulfate	CAPSULE;ORAL	021879-001	Oct 29, 2010	AB	RX	Yes	Yes	7,659,282
Avanir Pharms	ONZETRA XSAIL	sumatriptan succinate	POWDER;INHALATION	206099-001	Jan 27, 2016		RX	Yes	Yes	8,899,229		Y
Avanir Pharms	ONZETRA XSAIL	sumatriptan succinate	POWDER;INHALATION	206099-001	Jan 27, 2016		RX	Yes	Yes	8,327,844

Expired US Patents for Avanir Pharms

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Avanir Pharms	NUEDEXTA	dextromethorphan hydrobromide; quinidine sulfate	CAPSULE;ORAL	021879-001	Oct 29, 2010	5,166,207
Avanir Pharms	NUEDEXTA	dextromethorphan hydrobromide; quinidine sulfate	CAPSULE;ORAL	021879-001	Oct 29, 2010	5,206,248
Avanir Pharms	NUEDEXTA	dextromethorphan hydrobromide; quinidine sulfate	CAPSULE;ORAL	021879-001	Oct 29, 2010	RE38115

Paragraph IV (Patent) Challenges for AVANIR PHARMS drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Capsules	20 mg/10 mg		2011-03-07

International Patents for Avanir Pharms Drugs

Country	Document Number	Estimated Expiration
Russian Federation	2428217
Cyprus	1111201
World Intellectual Property Organization (WIPO)	02068029
Japan	2008531101
World Intellectual Property Organization (WIPO)	2004006930

Supplementary Protection Certificates for Avanir Pharms Drugs

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
C0062	France		PRODUCT NAME: (A) DEXTROMETHORPHAN OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, PAR EXEMPLE LE BROMHYDRATE DE DEXTROMETHORPHAN ET EN PARTICULIER LE MONOHYDRATE DE BROMHYDRATE DE DEXTROMETHORPHAN (B) QUINIDINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, PAR EXEMPLE LE SULFATE DE QUINIDINE EN PARTICULIER LE DIHYDRATE DE SULFATE DE QUINIDINE; REGISTRATION NO/DATE: EU/1/13/833/001-003 20130626
2013 00059	Denmark		PRODUCT NAME: KOMBINATION AF (A) DEXTROMETHORPHAN OG (B) QUNIDIN, HERUNDER DEXTROMETHORPHANHYDROBROMIDMONOHYDRAT OG QUINIDINSULFATDIHYDRAT; REG. NO/DATE: EU/1/13/833 20130624
1	Finland
0130030 00105	Estonia		PRODUCT NAME: DEKSTROMETORFAAN / KINIDIIN;REG NO/DATE: K(2013)4096 (LOPLIK) 26.06.2013
13/055	Ireland		PRODUCT NAME: THE COMBINATION OF: (A) DEXTROMETHORPHAN OR A PHARMACEUTICALLY ACCEPTABLE SALT, PRECURSOR OR DERIVATIVE THEREOF, E.G. DEXTROMETHORPHAN HYDROBROMIDE AND IN PARTICULAR DEXTROMETHORPHAN HYDROBROMIDE MONOHYDRATE; AND (B) QUINIDINE OR A PHARMACEUTICALLY ACCEPTABLE SALT, PRECURSOR OR DERIVATIVE THEREOF, E.G. QUINIDINE SULPHATE AND IN PARTICULAR QUINIDINE SULPHATE DIHYDRATE, PROTECTED BY THE BASIC PATENT; REGISTRATION NO/DATE: EU/1/13/833 20130624

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Avanir Pharms
• Avanthi Inc